Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors

被引：0
|
作者：
Meng, Yanchun
Zhang, Jian
Zhao, Chuanhua
Cheng, Ying
Zhu, Liming
Song, Zhengbo
Xu, Nong
Wang, Zhen
Wang, Yanping
Du, Yiqun
Jing, Deqiang
Chen, Dinglu
Qu, Qiaofeng
Zhao, Xiwen
Li, Wei
Lu, Qiying
Tian, Wenzhi
Xu, Jianming
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Phase Clin Trial Ctr 1, Shanghai, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[3] Sch Med, Beijing, Peoples R China
[4] Jilin Canc Hosp, Changchun, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[7] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[8] ImmuneOnco Biopharmaceut Shanghai Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15185
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.
    Patnaik, A.
    Appleman, L. J.
    Mountz, J. M.
    Ramanathan, R. K.
    Beeram, M.
    Tolcher, A. W.
    Papadopoulos, K. P.
    Lotze, M. T.
    Petro, D. P.
    Laymon, C.
    Paige, L.
    Rajagopalan, P.
    Jeffers, M.
    Roth, D.
    Dubowy, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
    Yu, Xianjun
    Zhang, Jian
    Sun, Yuping
    Deng, Yanhong
    Guo, Shuangshuang
    Hong, Wei
    Shi, Si
    Liu, Rujiao
    Gao, Shuiping
    Dang, Qi
    Zhang, Jianwei
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Zhang, Bo
    Pan, Beiqing
    Jia, Xiaoyun
    Wang, Jian
    Zhong, Chen
    Ma, Luguang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] First-in-human phase I dose-escalation study of the oral selective C-met inhibitor EMD 1204831 in patients with advanced solid tumors.
    Amin, Hesham M.
    Falchook, Gerald Steven
    Fu, Siqing
    Hong, David S.
    Tsimberidou, Apostolia Maria
    Naing, Aung
    Wheler, Jennifer J.
    Piha-Paul, Sarina Anne
    Janku, Filip
    Klevesath, Manfred B.
    Jego, Virginie
    Johne, Andreas
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study
    Yao, Herui
    Yan, Min
    Tong, Zhongsheng
    Wu, Xinhong
    Ryu, Min-Hee
    Kim, Jee Hyun
    Park, John
    Zhong, Yahua
    Han, Weiqing
    Liu, Caigang
    Voskoboynik, Mark
    Qin, Qun
    Zhang, Jian
    Barve, Minal
    Acuna-Villaorduna, Ana
    Ganju, Vinod
    Im, Seock-Ah
    Ye, Changsheng
    Yin, Yongmei
    Roy, Amitesh C.
    Bai, Li-Yuan
    Lin, Yung-Chang
    Yen, Chia-Jui
    Li, Hui
    Chung, Ki Young
    Gu, Shanzhi
    Qian, Jun
    Teng, Yuee
    Chen, Yiding
    Shen, Yu
    Zhao, Kaijing
    Rong, Shangyi
    Zhu, Xiaoyu
    Song, Erwei
    CANCER RESEARCH, 2023, 83 (08)
  • [45] First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors: phase I dose finding part results
    Yamamoto, Noboru
    Sato, Jun
    Iwasa, Satoru
    Yonemori, Kan
    Koyama, Takafumi
    Tamura, Kenji
    Shimizu, Toshio
    Kondo, Syunsuke
    Kitano, Shigehisa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [46] A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.
    Capelan, Marta
    Kumar, Prasana
    Tolcher, Anthony W.
    Zivi, Andrea
    Desai, Madhuri
    Papadopoulos, Kyriakos P.
    Senaldi, Giorgio
    Patnaik, Amita
    Banerji, Udai
    Rasco, Drew D.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [47] Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
    Hu, Xichun
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Wu, Junyan
    Wang, Ying
    Hao, Yanrong
    Ge, Junyou
    Qing, Yan
    Yi, Shuli
    Yang, Qixian
    Rao, Huajing
    Yuan, Juanjuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
    Elena Elez, Maria
    Tabernero, Josep
    Geary, David
    Macarulla, Teresa
    Kang, S. Peter
    Kahatt, Carmen
    Soto-Matos Pita, Arturo
    Fernandez Teruel, Carlos
    Siguero, Mariano
    Cullell-Young, Martin
    Szyldergemajn, Sergio
    Ratain, Mark J.
    CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2205 - 2214
  • [49] A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
    Koganemaru, S.
    Yoshizuka, N.
    Mizuno, S.
    Hirai, S.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S531 - S531
  • [50] The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
    LoRusso, Patricia
    Yamamoto, Noboru
    Patel, Manish R.
    Laurie, Scott A.
    Bauer, Todd M.
    Geng, Junxian
    Davenport, Teffany
    Teufel, Michael
    Li, Jian
    Lahmar, Mehdi
    Gounder, Mrinal M.
    CANCER DISCOVERY, 2023, 13 (08) : 1802 - 1813
12345